Commercial Credit Report for Neuland Laboratories Ltd (Parent)

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Neuland Laboratories Ltd (Parent) is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Neuland Laboratories Ltd (Parent)
'A' Block, Ground Floor, 8-2-120/113
Rd No 2, Banjara Hills, Sanali Info Park
Phone: +91 4067611600p:+91 4067611600	HYDERABAD, 500033 India	Fax: +91 4067611600f:+91 4067611600

Business Summary

Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.

(Source: ARS)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2023	3/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations

Officers and Directors

Title	Name	Title Date	Start Date
Executive Chairman of the Board	Davuluri R.Rao	1/1/2021
Chief Executive Officer, Whole Time Vice Chairman of the Board	Davuluri S.Rao	5/20/2016
Whole Time Vice Chairman of the Board, Joint Managing Director	Davuluri S.Rao	1/1/2021	6/1/2009
7 additional Officers and Directors records available in full report.

General Information

Outstanding Shares:	12,829,889	(As of 3/31/2023)
Fax Number:	+91 4067611600

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN